MC

701.9

+0.8%↑

SAF

244

-1.69%↓

MUV2

513.6

-0.35%↓

PUB

102.75

+0.69%↑

SAB2

2.521

+0.64%↑

MC

701.9

+0.8%↑

SAF

244

-1.69%↓

MUV2

513.6

-0.35%↓

PUB

102.75

+0.69%↑

SAB2

2.521

+0.64%↑

MC

701.9

+0.8%↑

SAF

244

-1.69%↓

MUV2

513.6

-0.35%↓

PUB

102.75

+0.69%↑

SAB2

2.521

+0.64%↑

MC

701.9

+0.8%↑

SAF

244

-1.69%↓

MUV2

513.6

-0.35%↓

PUB

102.75

+0.69%↑

SAB2

2.521

+0.64%↑

MC

701.9

+0.8%↑

SAF

244

-1.69%↓

MUV2

513.6

-0.35%↓

PUB

102.75

+0.69%↑

SAB2

2.521

+0.64%↑

Search

Bayer AG

Closed

Sector Finance

22.02 1.24

Overview

Share price change

24h

Current

Min

21.97

Max

22.09

Key metrics

By Trading Economics

Income

-4.2B

-4.2B

Sales

-1.2B

10B

P/E

Sector Avg

30.9

26.698

EPS

-4.258

Dividend yield

0.51

Profit margin

-42.075

Employees

94,245

EBITDA

-671M

1.1B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+19.41 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.51%

3.82%

Next Earnings

5 Mar 2025

Market Stats

By TradingEconomics

Market Cap

-2K

21B

Previous open

20.78

Previous close

22.02

News Sentiment

By Acuity

6%

94%

7 / 545 Finance

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Bayer AG Chart

Past performance is not a reliable indicator of future results.

Related News

12 Nov 2024, 09:32 UTC

Earnings

Bayer Cuts Earnings Target, Warns on Weak Agriculture Market -- Update

12 Nov 2024, 07:21 UTC

Earnings

Bayer Cuts Earnings Target, Posts Net Loss on Agriculture Weakness

13 Jan 2025, 21:05 UTC

Top News

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9 Jan 2025, 15:06 UTC

Acquisitions, Mergers, Takeovers

Bayer Didn't Disclose Financial Details

9 Jan 2025, 15:05 UTC

Acquisitions, Mergers, Takeovers

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

9 Jan 2025, 15:05 UTC

Acquisitions, Mergers, Takeovers

Bayer: Camelina Is Novel Intermediate Oilseed Crop

9 Jan 2025, 15:04 UTC

Acquisitions, Mergers, Takeovers

Bayer: Smart Earth Camelina Is Headquartered in Saskatoon, Saskatchewan, Canada

9 Jan 2025, 15:03 UTC

Acquisitions, Mergers, Takeovers

Bayer: Deal Expands Position in Biomass-Based Feedstock Markets

9 Jan 2025, 15:02 UTC

Acquisitions, Mergers, Takeovers

Bayer Acquires Camelina Germplasm, Intellectual Property Assets

9 Jan 2025, 15:02 UTC

Acquisitions, Mergers, Takeovers

Bayer, Smart Earth Camelina Corp Have Closed Deal

9 Jan 2025, 15:01 UTC

Acquisitions, Mergers, Takeovers

Bayer Acquires Camelina Assets From Smart Earth Camelina Corp

8 Jan 2025, 13:07 UTC

Acquisitions, Mergers, Takeovers

Bayer Doesn't Disclose Financial Details

8 Jan 2025, 13:06 UTC

Acquisitions, Mergers, Takeovers

Bayer: Vividion and Tavros Have Been Working Together for the Past Two Years

8 Jan 2025, 13:05 UTC

Acquisitions, Mergers, Takeovers

Bayer: Acquisition Will Expand Functional Genomics Capabilities, Boost Drug Discovery Platform

8 Jan 2025, 13:05 UTC

Acquisitions, Mergers, Takeovers

Bayer: Tavros Therapeutics Is a Precision Oncology Platform Company

8 Jan 2025, 13:04 UTC

Acquisitions, Mergers, Takeovers

Bayer: Acquisition Builds on Successful Collaboration Focused on Promising Drug Targets in Oncology

8 Jan 2025, 13:03 UTC

Acquisitions, Mergers, Takeovers

Bayer: Vividion Therapeutics Is a Wholly Owned and Independently Operating Subsidiary of Bayer

8 Jan 2025, 13:02 UTC

Acquisitions, Mergers, Takeovers

Bayer: Vividion Therapeutics to Acquire Tavros Therapeutics

12 Nov 2024, 16:39 UTC

Market Talk

Despite Rhetoric, Bayer CEO Says Pesticides Needed -- Market Talk

12 Nov 2024, 10:16 UTC

Market Talk
Earnings

Bayer's Pharmaceutical Sales Beat Market Expectations -- Market Talk

12 Nov 2024, 09:53 UTC

Earnings
Hot Stocks

Stocks to Watch Tuesday: Tesla, SoftBank, Spirit Airlines, Home Depot -- WSJ

12 Nov 2024, 09:43 UTC

Market Talk
Earnings

Bayer's Earnings Came in Below Market Expectations -- Market Talk

12 Nov 2024, 07:53 UTC

Top News
Earnings

Correct: Analysts Had Forecast Bayer 3Q Net Loss of EUR579M

12 Nov 2024, 07:02 UTC

Earnings

AstraZeneca Had Seen 2024 Core EPS Growth by Mid Teens Percentage Range

12 Nov 2024, 07:02 UTC

Earnings

AstraZeneca Sees 2024 Core EPS Growth In High Teens Percentage Range

12 Nov 2024, 07:02 UTC

Earnings

AstraZeneca Had Seen 2024 Total Revenue Growth In Mid Teens Percentage Range

12 Nov 2024, 07:02 UTC

Earnings

AstraZeneca Sees 2024 Total Revenue Growth In High Teens Percentage Range

12 Nov 2024, 07:02 UTC

Earnings

AstraZeneca Raises 2024 View

12 Nov 2024, 07:01 UTC

Earnings

Analysts Saw AstraZeneca 3Q Sales at $13.1B

12 Nov 2024, 07:01 UTC

Earnings

Analysts Saw AstraZeneca 3Q Core EPS at $2.04

Peer Comparison

Price change

Bayer AG Forecast

Price Target

By TipRanks

19.41% upside

12 Months Forecast

Average 26.33 EUR  19.41%

High 33 EUR

Low 22 EUR

Based on 7 Wall Street analysts offering 12 month price targets forBayer AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

7 ratings

1

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

21.62 / N/ASupport & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

7 / 545 Finance

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.